CD8A and neuroblastoma: On the other hand, we propose that in the absence of CD8+ T-mediated immunity, CD4 CTLs can target the HLA-E+ high-risk neuroblastoma cells in a TCR- and HLA-independent manner, which in turn would be unaffected by the PD-L1 expression status on the neuroblastoma cells.